Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Aligos Therapeutics Inc
(NQ:
ALGS
)
0.5251
+0.0450 (+9.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aligos Therapeutics Inc
< Previous
1
2
3
Next >
Aligos Therapeutics Announces Reverse Stock Split
August 15, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Strengthens Board with Two New Independent Directors
August 08, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2024 Financial Results
August 06, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 2nd Quarter 2024 Financial Results on August 6, 2024
July 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.
July 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB
July 10, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Data at the EASL Congress 2024
June 05, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024
May 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH
May 21, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
May 07, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
April 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
April 25, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
April 25, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
April 09, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
April 03, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
March 27, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
March 18, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
March 12, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
March 05, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024
February 26, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024
February 20, 2024
Event to feature KOL perspective on emerging MASH therapies
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Strengthens Finance Leadership Team with Two New Appointments
February 13, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)
December 07, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference
November 20, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile
November 13, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)
November 10, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present Multiple Posters at AASLD’s The Liver Meeting® 2023, Highlighting Progress for Its Clinical Stage Portfolio, including Lead THR-β Agonist for the Treatment of NASH, ALG-055009; ALG-000184, the Company’s Lead CAM-E Molecule,
November 07, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Host KOL Event to Discuss ALG-000184 Phase 1, AASLD Late Breaker Data
November 03, 2023
November 16 Event to feature KOL perspective on Emerging HBV Therapies
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
November 02, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023
October 26, 2023
From
Aligos Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.